Evidence map›Paper›PMID 40608229›Full record

ReviewMolecular diversity2026

Drug repurposing: a promising drug discovery strategy for the treatment of emerging epidemic infectious disease.

Simeng Zhang, Ruiqing Zhang, Lidan Zheng, Yang Liu, Qing Fan, Yingxu Liu, Xiangzhen Ning, Yanmin Zhang, Yadong Chen, Haichun Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Artificial intelligence in respiratory medicine: From diagnosis to treatment and future directions.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Simeng Zhang *Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Ruiqing Zhang *Children's Hospital of Nanjing Medical University, Nanjing, 210009, China.
Lidan ZhengLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Yang LiuLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Qing FanLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Yingxu LiuLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Xiangzhen NingLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Yanmin ZhangLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Yadong ChenLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Haichun LiuLaboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China. haichunliu@cpu.edu.cn.

Funding

National Natural Science Foundation of China 82073704Natural Science Foundation of Jiangsu Province BK20190549
6 · The paper itself

Abstract

Epidemic refers to a disease when the occurrence level exceeds expected standards (generating an epidemic phenomenon), in which infectious diseases pose a major challenge to global health. The concept of epidemiology arises with infectious diseases, which can infect many people within a certain period and lead to a pandemic. Especially in the face of sudden epidemics, time is of the essence. In such urgent scenarios, the time required for traditional drug discovery is often prohibitive, given its inherently long timelines, high costs, and frequent failures. Drug repurposing strategies, mainly divided into experimental and computational approaches,which involves identifying new therapeutic applications for already approved pharmaceuticals, have gained substantial attention as a time-efficient and cost-effective alternative. In light of this, the present review provides a comprehensive overview of the various approaches to drug repurposing for the treatment of emerging epidemic infectious diseases, the majority of which are sudden epidemics caused by viruses. In addition, we discuss the challenges faced by repurposing and propose innovative approaches to address these challenges to better achieve the successful translation of drug repurposing into clinical applications and maximize the therapeutic value of drugs.

Indexed as

Communicable Diseases, EmergingDrug DiscoveryDrug RepositioningAntiviral AgentsEpidemicsHumansAntiviral AgentsClinical applicationDrug discovery strategyDrug repurposingEpidemicGlobal healthInfectious diseases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.